Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 most active penny stocks to buy. Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi Analyst sentiment toward Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) remains constructive. With 73% of covering analysts retaining bullish ratings, the consensus price target of $9.50 suggests a potential upside of 135.15% as of March 16, 2026. On March 11, 2026, at the Barclays 28th Annual Global Heal ...